Swiss AI Firm Raises Funds for Entry into U.S.

Sophia Genetics will establish U.S. office and expand their AI platform into new hospital systems.

Swiss-based Sophia Genetics has developed its Sophia AI analytics platform to evaluate genomic and radiomic data with the goal of aiding the diagnosis of patients with cancer and hereditary disorders. According to the company, the program is used by more than 850 hospitals in 77 countries.

A successful Series E funding round will make it possible for Sophia Genetics to establish a U.S. headquarters in Boston and increase the number of hospitals using its AI platform. The company raised $77 million in new venture capital, bringing the total funding it has raised to $140 million. The latest round was led by Generation Investment Management (co-founded and chaired by former U.S. Vice President Al Gore) and included participation by Idinvest Partners, Balderton Capital and Alychlo — the latter two have previously backed Sophia.

Cynthia A. Challener, Ph.D.

Dr. Challener is an established industry editor and technical writing expert in the areas of chemistry and pharmaceuticals. She writes for various corporations and associations, as well as marketing agencies and research organizations, including That’s Nice and Nice Insight.